KLOW

Quickstart Highlights

KLOW is a four-peptide repair blend supplied in a fixed 5:1:1:1 ratio: 50 mg of GHK-Cu with 10 mg each of BPC-157, TB-500 and KPV in a single 80 mg vial. Research-community protocols use the combination for soft-tissue and tendon recovery, skin and collagen remodelling, and gut or systemic inflammation, although no published study has tested the four peptides together. This educational protocol presents once-daily subcutaneous injections over a 4–6 week cycle, starting at 2 mg of blend and moving to 4 mg from week 3, using a 2.4 mL reconstitution so that the common 250 mcg and 500 mcg per-peptide points fall on whole insulin-syringe units.

• Reconstitute: Add 2.4 mL bacteriostatic water → 33.33 mg/mL concentration.
• Dose range: 2–4 mg of total blend once daily, subcutaneously, delivering 250–500 mcg each of BPC-157, TB-500 and KPV plus 1.25–2.5 mg GHK-Cu (4–6 week cycle, then 2–4 weeks off).
• Easy measuring: At 33.33 mg/mL, 1 unit = 0.01 mL = 333.33 mcg of blend (about 208 mcg GHK-Cu + 41.7 mcg each of BPC-157, TB-500 and KPV) on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.
• Cycle note: Sources build in an off period because of the copper carried by GHK-Cu; the blend delivers 1.25–2.5 mg of GHK-Cu per day, so 4–6 weeks on is followed by 2–4 weeks off.

Protocol Overview

Concise summary of the once-daily four-peptide repair regimen.

• Goal: Support soft-tissue, tendon and skin repair while reducing inflammation by combining GHK-Cu, BPC-157, TB-500 and KPV in one daily injection.
• Schedule: Daily subcutaneous injections, placed near the injury site where practical, for 4–6 weeks followed by a 2–4 week break.
• Dose Range: 2 mg of total blend daily (250 mcg each of BPC-157, TB-500 and KPV plus 1.25 mg GHK-Cu) in weeks 1–2, rising to 4 mg daily (500 mcg each plus 2.5 mg GHK-Cu) from week 3; in syringe terms 2000–4000 mcg of blend per injection.
• Reconstitution: 2.4 mL per 80 mg vial (33.33 mg/mL) for accurate unit measurements on standard insulin syringes.
• Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 28 days; avoid repeated freeze–thaw cycles.
• Evidence: Community convention with no human data for the combination: every source states that no published study has evaluated the four-peptide KLOW blend, and the components themselves rest on animal data and small pilots (BPC-157, TB-500, KPV) or topical and gene-expression work (GHK-Cu). Confidence is low; the unit-based convention is vendor-propagated and one source differs from the others by tenfold.

Dosing Protocol

Suggested daily approach based on research-community blend conventions and the single-peptide ranges of each component.

• Weeks 1–2: 2 mg of blend (2000 mcg) once daily, which delivers 250 mcg each of BPC-157, TB-500 and KPV plus 1.25 mg GHK-Cu; 6 units at the 2.4 mL reconstitution.
• Week 3 onward: 4 mg of blend (4000 mcg) once daily, which delivers 500 mcg each of BPC-157, TB-500 and KPV plus 2.5 mg GHK-Cu; 12 units.
• Frequency: Once daily, subcutaneously, near the injury site where practical. Higher-volume days may be split into morning and evening injections.
• Timing: No convention exists for morning versus evening; sources describe either. Keep the time of day consistent and record the site used.
• Cycle: 4–6 weeks on, then 2–4 weeks off. The off period is driven by the copper load from GHK-Cu, not by the three smaller peptides. Sources describe an extended 8–12 week option with 4–8 weeks off, which is outside this page.
• Titration: Most sources start at the working dose; this page holds the 2 mg amount for two weeks before stepping to 4 mg so that injection-site tolerance and copper-related symptoms can be observed first.
• Maintenance: At the end of the cycle, sources describe either stopping entirely or dropping to two or three injections per week; the standard approach is a full break before any repeat cycle.

Storage Instructions

Proper storage preserves product quality and efficacy.

• Lyophilized (powder): Store at −20 °C (−4 °F) for long-term storage, or refrigerated at 2–8 °C (35.6–46.4 °F) for short periods, dry and protected from light.
• Reconstituted (solution): Refrigerate at 2–8 °C (35.6–46.4 °F), protected from light, and do not freeze. Use within 28 days; sources range from 14 to 42 days, so 28 days is the working ceiling on this page.
• Allow the vial to reach room temperature before opening to minimize condensation uptake.
• A clear solution with a light-blue tint is normal and comes from the copper in GHK-Cu; a change to cloudiness or visible particulates is a reason to discard the vial.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a proper sharps container.
• Rotate injection sites systematically (abdomen, thighs, upper arms); where the goal is a specific injury, sources describe placing the injection near that site, with the surrounding skin rotated day to day.
• The dose is a fixed ratio: at 2.4 mL, 1 unit contains about 208 mcg GHK-Cu plus 41.7 mcg each of BPC-157, TB-500 and KPV. The 2 mg and 4 mg steps match the 250 mcg and 500 mcg points used for BPC-157 on its own, and the GHK-Cu share lands inside the usual 1–3 mg daily range for that peptide.
• Copper load from GHK-Cu is the main safety consideration. Metallic taste, unusual fatigue, nausea or abdominal pain during the cycle are described as signs of copper accumulation; sources recommend monitoring copper and zinc on longer protocols and keeping the off period.
• Not approved by Health Canada or the FDA; research use only. BPC-157 and TB-500 are prohibited by WADA, so the blend is unsuitable for tested athletes.
• Evidence caveat: no published study has evaluated the four-peptide KLOW combination, and the unit-based convention comes from vendor and dosing-site pages. The 10–20 units/day at 3 mL convention is shared by five of six blend sources, but one source gives a figure roughly tenfold lower.
• Contraindications cited by sources: active or recent cancer (angiogenesis from BPC-157, TB-500 and GHK-Cu), Wilson’s disease or other copper-metabolism disorders, pregnancy and WADA-tested sport.
• TB-500 in this blend is delivered at sub-milligram amounts daily, not in the 2–2.5 mg twice-weekly loading pattern used for standalone TB-500; do not add a separate TB-500 loading schedule on top of the blend.

How This Works

KLOW combines four repair-oriented peptides in a fixed 5:1:1:1 ratio, and the rationale described by sources is that each one acts on a different stage of tissue repair. GHK-Cu is a copper-binding tripeptide that delivers copper to the tissue and drives collagen and elastin synthesis, remodelling and skin repair; it is the component with the most human data, mostly from topical and gene-expression studies. BPC-157 upregulates VEGF and growth-factor signaling, promoting angiogenesis and tendon and soft-tissue healing in animal models. TB-500 sequesters actin, which promotes cell migration into injured tissue and new vessel formation. KPV, the C-terminal tripeptide of alpha-MSH, suppresses NF-kB-driven inflammation without the pigmentation effects of the full hormone. Sources describe the combination as overlapping repair pathways delivered in one injection, with the GHK-Cu share determining the cycle length because of its copper content. No study has tested the four peptides together, so the mechanism is inferred from each component separately.

Potential Benefits & Side Effects

Observations from animal and early human literature on the individual components; the combination itself has not been studied.

Potential Benefits:

• Combined soft-tissue, tendon and joint repair, based on BPC-157 and TB-500 animal models of tendon, ligament and muscle healing.
• Skin quality, collagen remodelling and hair or nail improvement attributed to GHK-Cu, which has human topical and gene-expression data.
• Gut and systemic anti-inflammatory support from KPV and BPC-157, shown in mouse colitis and cell models.
• Wound-healing acceleration reported by community sources around weeks 3–4 of a cycle.
• Angiogenesis and cell migration to injury sites in animal models, which is also the basis of the cancer contraindication.

Potential Side Effects:

• Injection-site redness, swelling or sensitivity; a light blue-green tint at the site from GHK-Cu is cosmetic.
• Transient fatigue in the first 1–2 weeks (attributed to TB-500), headache, light-headedness, nausea, vivid dreams or appetite change.
• Copper accumulation with prolonged GHK-Cu use: metallic taste, fatigue, nausea and abdominal pain; copper and zinc monitoring is described for long protocols.
• Angiogenesis concern: active or recent cancer is listed as a contraindication for three of the four components.
• A temporary flare of old injuries is reported as uncommon by one source.
• Interactions among the four peptides are unknown; no human safety data exist for the combination.

Lifestyle Factors

Complementary strategies for a tissue-repair protocol.

• Maintain adequate protein intake (1.2–1.6 g/kg body weight) and total calories so that collagen and tissue synthesis have the raw material to use.
• Load the recovering tissue progressively under qualified guidance; controlled mechanical loading, not rest alone, directs tendon and ligament remodelling.
• Include dietary sources of vitamin C and zinc, which support collagen cross-linking and balance the copper delivered by GHK-Cu.
• Prioritize 7–9 hours of sleep, when most tissue repair and growth-hormone release occurs.
• Avoid smoking and limit alcohol, both of which impair angiogenesis and wound healing.
• Keep a simple log of injection site, dose and symptoms such as metallic taste or fatigue so that copper-related effects are caught early.

Injection Technique

General subcutaneous injection guidance from clinical best-practice resources.

• Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding.
• Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle).
• Do not aspirate (pull back the plunger) when giving a subcutaneous injection.
• Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
• Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and maintain consistent absorption.
• Dispose of used syringes and needles immediately in a proper sharps container.

Recommended Source

We recommend Amino Labs for high-purity KLOW (80 mg vials).

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs